Biopharmaceuticals represent some of the most advanced achievements of modern science. Since their introduction, biologic therapies have become central to treatment for a range of disease from Rheumatoid Arthritis to Crohn's Disease and Multiple Sclerosis.
However, substantial pharmacodynamics and pharmacokinetic variation can occur across a patient population and also as a patient progresses through treatment. Such variability can significantly affect drug exposure resulting in sub-optimal dosing.
Historically dose monitoring has been an "add-on" to clinical practice and has limited utility due to the amount of time it takes to provide the physician with actionable information.
Our solution for these issues is to develop treatments as Integrated Therapeutics where personalized precision dosing using our Veritope technology is incorporated into the development of a biopharmaceutical therapy.
Our lead program ABR101 will study low-dose rituximab integrated with Veritope technology in the treatment of Relapse Remitting Multiple Sclerosis. Additional programs will continue to be added to our Integrated Therapeutics pipeline.